Abstract:The Chimera antigen receptor (CAR)-T cell therapy has gained great success in the clinic. However, there are still major challenges for its wider applications in a variety of cancer types including lack of effectiveness due to the highly complex tumor microenvironment, and the forbiddingly high cost due to the personalized manufacturing procedures. In order to overcome these hurdles, numerous efforts have been spent focusing on optimizing Chimera antigen receptors, engineering and improving T cell capacity, exploiting features of subsets of T cell or NK cells, or making off-the-shelf universal cells. Here, in the first part, we developed induced pluripotent stem cells (iPSCs)-derived, CAR-expressing macrophage cells (CAR-iMac). CAR expression confers antigen-dependent macrophage functions such as expression and secretion of cytokines, enhanced phagocytosis of tumor cells, and in vivo anticancer cell activity. This technology platform for the first time provides an unlimited source of iPSC-derived engineered CAR-macrophage cells which could be utilized to eliminate cancer cells. In the second part, we focus on the "second generation” of CAR-iMac and its applications in solid tumors. Therapeutic effects of CAR-T cells on solid tumors remains to be improved. CAR-macrophages have attracted much attention in solid tumor, given their ability to phagocytize tumor cells and their immunomodulatory capacities in the TME. The first generation of engineered CAR-iMac demonstrated that the CAR could stimulate macrophage phagocytosis in a tumor antigen-dependent way. For the second generation of CAR-iMac, after careful screening and rational designs, we genetically engineered iPSC-derived macrophages (iMACs) with Toll-like Receptor intracellular TIR domain-containing CARs against EGFRvIII and GPC3, which yielded an enhanced antitumor effect in two different tumor types . Moreover, CD3ζ-TIR-CAR, the second generation design of TIR-based dual signaling CAR, endowed iMACs with both target engulfment/trogocytosis capacity against antigen-expressing solid tumor cells, and potency of antigen-dependent M1-polarization and M2-like state resistance in an NF-κB dependent manner. Taken together, we established the next generation CAR-iMACs equipped with enhanced phagocytosis and polarization capacity for better antitumor functions in treating liquid and solid tumors. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Large-scale generation of IL12 secreting macrophages from human pluripotent stem cells for cancer therapy

Large-scale Generation of IL-12 Secreting Macrophages from Human Pluripotent Stem Cells for Cancer Therapy

The Second Generation of Human Ipsc-Derived CAR-Macrophages for Immune Cell Therapies in Liquid and Solid Tumors

3176 – EFFECTIVE PRODUCTION OF HIGHLY FUNCTIONAL CAR-MACROPHAGES FROM HUMAN PLURIPOTENT STEM CELLS FOR CANCER IMMUNOTHERAPY

Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity

Combination of GNRs-PEI/cGAMP-laden Macrophages-Based Photothermal Induced in Situ Tumor Vaccines and Immune Checkpoint Blockade for Synergistic Anti-Tumor Immunotherapy.

Tumor‐Associated Macrophage and Tumor‐Cell Dually Transfecting Polyplexes for Efficient Interleukin‐12 Cancer Gene Therapy

Generation of Anti-Gd2 CAR Macrophages from Human Pluripotent Stem Cells for Cancer Immunotherapies

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma

Induced Pluripotent Stem Cell-derived CAR-Macrophage Cells with Antigen-dependent Anti-Cancer Cell Functions for Liquid and Solid Tumors

Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer

Homology-independent targeted insertion-mediated derivation of M1-biased macrophages harbouring Megf10 and CD3ζ from human pluripotent stem cells

Artificially Reprogrammed Macrophages As Tumor‐Tropic Immunosuppression‐Resistant Biologics to Realize Therapeutics Production and Immune Activation

Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions

A Multi-Functional Macrophage And Tumor Targeting Gene Delivery System For The Regulation Of Macrophage Polarity And Reversal Of Cancer Immunoresistance

Large-Scale Production of Human iPSC-Derived Macrophages for Drug Screening

CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy

Generation of hypoimmunogenic human pluripotent stem cells via expression of membrane-bound and secreted β2m-HLA-G fusion proteins

A Tumor-Selective Biotherapy with Prolonged Impact on Established Metastases Based on Cytokine Gene-Engineered MSCs.

Development and Characterization of Naive Single-Type Tumor Antigen-Specific CD8(+) T Lymphocytes from Murine Pluripotent Stem Cells

Cell Membrane-Anchored and Tumor-Targeted IL-12 (Attil12)-T Cell Therapy for Eliminating Large and Heterogeneous Solid Tumors